Pivot Point Capital Partners Exits Position in The Advisory Board Company (ABCO)

The Advisory Board Company (ABCO) : Pivot Point Capital Partners has sold out all of its stake in The Advisory Board Company during the most recent quarter, according to the disclosure filed by the company on Nov 14, 2016 with the SEC. The investment management company has sold out 13,034 shares of The Advisory Board Company which is valued at $428,167.

Other Hedge Funds, Including , Two Sigma Investments Lp reduced its stake in ABCO by selling 177,720 shares or 96.0% in the most recent quarter. The Hedge Fund company now holds 7,402 shares of ABCO which is valued at $243,156.Swiss National Bank reduced its stake in ABCO by selling 3,800 shares or 5.45% in the most recent quarter. The Hedge Fund company now holds 65,900 shares of ABCO which is valued at $2,286,730. First Personal Financial Services added ABCO to its portfolio by purchasing 234 company shares during the most recent quarter which is valued at $8,120. First Trust Advisors Lp added ABCO to its portfolio by purchasing 33,059 company shares during the most recent quarter which is valued at $1,205,001. Capital Fund Management S.a. added ABCO to its portfolio by purchasing 6,100 company shares during the most recent quarter which is valued at $242,170.

The Advisory Board Company opened for trading at $35.85 and hit $36.95 on the upside on Monday, eventually ending the session at $35.95, with a gain of 0.70% or 0.25 points. The heightened volatility saw the trading volume jump to 4,97,211 shares. Company has a market cap of $1,443 M.

On the company’s financial health, The Advisory Board Company reported $0.28 EPS for the quarter, missing the analyst consensus estimate by $ -0.12 based on the information available during the earnings call on Nov 1, 2016. Analyst had a consensus of $0.40. The company had revenue of $200.50 million for the quarter, compared to analysts expectations of $203.35 million. During the same quarter in the previous year, the company posted $0.33 EPS.

Many Wall Street Analysts have commented on The Advisory Board Company. The Advisory Board Company was Downgraded by BofA/Merrill to ” Underperform” on Nov 7, 2016. Shares were Reiterated by Stifel on Nov 2, 2016 to “Hold” and Lowered the Price Target to $ 43 from a previous price target of $45 .

The Advisory Board Company is a provider of software and solutions to the healthcare and higher education industries. The Company’s healthcare programs address a range of clinical and business issues including physician alignment and engagement network management and growth strategy value-based care and population health revenue cycle clinical operations and supply chain. Its higher education programs support colleges and universities in enrollment management academic programming and student learning faculty recruitment and retention student advising and success alumni affairs and advancement and college and university operations. The Company offers approximately 65 distinct membership programs across four areas which include best practices research and insight performance technology software consulting and management services and data- and tech-enabled services. Its best practices research and insight programs provide the foundation for all of its other programs.

Leave a Reply

The Advisory Board Company - Is it time to Sell?

Top Brokerage Firms are advising their investors on The Advisory Board Company. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.